Quoin Pharmaceuticals Announces 50% Enrollment In Open Label Netherton Syndrome Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Quoin Pharmaceuticals has announced 50% enrollment in its open-label clinical trial for Netherton Syndrome, a rare genetic skin disorder.
May 24, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quoin Pharmaceuticals (QNRX) has reached 50% enrollment in its clinical trial for Netherton Syndrome, potentially bringing the company closer to a treatment for the rare skin disorder.
The 50% enrollment milestone in the clinical trial indicates progress in Quoin Pharmaceuticals' efforts to develop a treatment for Netherton Syndrome. This progress could positively impact QNRX's stock price in the short term as investors may see it as a sign of the company's potential to bring a new product to market.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100